Indivior Pharmaceuticals (INDV) Gross Margin (2024 - 2026)

Indivior Pharmaceuticals' Gross Margin history runs 3 years deep, the most recent figure standing at 87.38% for Q1 2026.

• On a quarterly basis, Gross Margin rose 430.0% year-over-year to 87.38% in Q1 2026; TTM through Mar 2026 was 81.25%, a 166.0% increase from a year earlier, with the FY2025 full-year figure at 80.23%, down 33.0% from the prior year.
• Gross Margin climbed to 87.38% in Q1 2026 per INDV's latest filing, from 81.56% in the prior quarter.
• Across five years, Gross Margin topped out at 87.38% in Q1 2026 and bottomed at 73.25% in Q3 2025.
• The 3-year median for Gross Margin is 82.78% (2025), against an average of 81.15%.
• Biggest YoY gain for Gross Margin was 920 bps in 2025; the steepest drop was 525 bps in 2025.
• Year by year, Gross Margin stood at 83.61% in 2024, then slipped by 2 bps to 81.56% in 2025, then increased by 7 bps to 87.38% in 2026.
• Per Business Quant, the three latest INDV Gross Margin figures stand at 87.38% (Q1 2026), 81.56% (Q4 2025), and 73.25% (Q3 2025).